Shares of Gilead Sciences, Inc. (NASDAQ:GILD) have received an average rating of “Buy” from the twenty-six brokerages that are presently covering the firm, Marketbeat Ratings reports. Ten investment analysts have rated the stock with a hold recommendation, fourteen have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month target price among brokers that have covered the stock in the last year is $88.51.
Several research firms have recently commented on GILD. BidaskClub cut Gilead Sciences from a “buy” rating to a “hold” rating in a research note on Wednesday, November 21st. ValuEngine upgraded Gilead Sciences from a “sell” rating to a “hold” rating in a research note on Saturday, December 1st. Cantor Fitzgerald restated an “overweight” rating and set a $92.00 price target on shares of Gilead Sciences in a research note on Wednesday, December 19th. Zacks Investment Research cut Gilead Sciences from a “buy” rating to a “hold” rating in a research note on Monday, December 31st. Finally, Evercore ISI restated a “buy” rating on shares of Gilead Sciences in a research note on Wednesday, October 31st.
GILD stock opened at $68.16 on Friday. The company has a market capitalization of $87.89 billion, a PE ratio of 7.96, a PEG ratio of -2.35 and a beta of 1.06. Gilead Sciences has a twelve month low of $60.32 and a twelve month high of $89.54. The company has a debt-to-equity ratio of 1.09, a current ratio of 3.45 and a quick ratio of 3.37.
Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Thursday, October 25th. The biopharmaceutical company reported $1.84 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.63 by $0.21. The business had revenue of $5.60 billion during the quarter, compared to the consensus estimate of $5.44 billion. Gilead Sciences had a return on equity of 39.32% and a net margin of 7.12%. During the same period in the prior year, the company earned $2.27 earnings per share. On average, sell-side analysts predict that Gilead Sciences will post 6.44 EPS for the current year.
The firm also recently disclosed a quarterly dividend, which was paid on Friday, December 28th. Shareholders of record on Friday, December 14th were given a $0.57 dividend. This represents a $2.28 annualized dividend and a yield of 3.35%. The ex-dividend date was Thursday, December 13th. Gilead Sciences’s payout ratio is 26.64%.
In other Gilead Sciences news, Director John C. Martin sold 50,000 shares of the stock in a transaction on Monday, December 3rd. The stock was sold at an average price of $71.20, for a total value of $3,560,000.00. Following the completion of the transaction, the director now owns 2,877,762 shares in the company, valued at $204,896,654.40. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 1.16% of the company’s stock.
A number of institutional investors have recently bought and sold shares of the business. Waldron Private Wealth LLC boosted its stake in shares of Gilead Sciences by 3.8% during the third quarter. Waldron Private Wealth LLC now owns 4,372 shares of the biopharmaceutical company’s stock valued at $337,000 after acquiring an additional 162 shares during the last quarter. Cornerstone Advisors Inc. boosted its stake in shares of Gilead Sciences by 6.1% during the third quarter. Cornerstone Advisors Inc. now owns 3,120 shares of the biopharmaceutical company’s stock valued at $241,000 after acquiring an additional 178 shares during the last quarter. North Star Investment Management Corp. boosted its stake in shares of Gilead Sciences by 11.5% during the fourth quarter. North Star Investment Management Corp. now owns 2,199 shares of the biopharmaceutical company’s stock valued at $138,000 after acquiring an additional 226 shares during the last quarter. Plimoth Trust Co. LLC boosted its stake in shares of Gilead Sciences by 0.8% during the third quarter. Plimoth Trust Co. LLC now owns 43,856 shares of the biopharmaceutical company’s stock valued at $3,386,000 after acquiring an additional 365 shares during the last quarter. Finally, Park National Corp OH boosted its stake in shares of Gilead Sciences by 7.9% during the fourth quarter. Park National Corp OH now owns 7,388 shares of the biopharmaceutical company’s stock valued at $463,000 after acquiring an additional 541 shares during the last quarter. 78.01% of the stock is currently owned by institutional investors.
Gilead Sciences Company Profile
Gilead Sciences, Inc discovers, develops, and commercializes therapeutics in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, and Tybost for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, Sovaldi, Viread, and Hepsera products for treating liver diseases.
Featured Article: What is a Futures Contract?
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.